FLAG Therapeutics
Fabric Store
Why pick this one
FLAG Therapeutics is focused on difficult-to-treat cancers and is advancing FLAG-003 for DIPG and GBM into clinical development in early 2026.
Best for
- Rare pediatric cancers
- New treatment options for GBM and DIPG
- Innovative drug development in oncology
Look elsewhere if
- Seeking treatments for common cancers
- Interested in non-oncology drug developments
Specialties
- Difficult-to-treat cancers
- Diffuse Intrinsic Pontine Glioma (DIPG)
- Glioblastoma Multiforme (GBM)
- Triple Negative Breast Cancer (TNBC)
- Ovarian Cancer
- Mesothelioma
- Pancreatic Cancer
Certifications
- Orphan Drug Designation
- Rare Pediatric Disease Designation
What makes them different
- Focused on developing new therapeutics for difficult-to-treat cancers
- Lead candidate FLAG-003 projected to enter Phase 1/2 clinical development in early 2026
- Over 100 issued patents in their intellectual property portfolio
- Exclusive licensing agreement with Duquesne University
- Preclinical studies show 100 percent response rate for FLAG-003 against GBM and DIPG
- Years in business
- 10
- Serves
- Raleigh
Distilled from this business's own website.
Contact & Location
- Address
- 9168 Wooden Rd, Raleigh, NC 27617
- Phone
- (919) 294-6472
- Website
- http://www.flagtherapeutics.com
- Info@FlagTherapeutics.com
Services
- Drug development
- Small molecule therapeutics